Skip to content

Study · Randomized controlled trial · n = 86 · 2013

6 results

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.

Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, Messing B, Loth S, Youssef NN, Heinze H, Berghöfer P

Clinical nutrition (Edinburgh, Scotland)28 Mar 2013Cited by 79 (Europe PMC)

PMID23587733 (opens in a new tab)DOI10.1016/j.clnu.2013.03.016 (opens in a new tab)PepBankPUB-23587733
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In SBS-IF patients, teduglutide did not significantly improve the SBS-QoL total score compared with placebo at week 24.

    In plain wordsIn SBS-IF patients, teduglutide did not significantly improve the total quality-of-life score compared with placebo.

    Peptide
    Teduglutide
    Outcome
    No significant changeSBS-QoL total score versus placebo
    Study

    n = 86

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.05 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    These changes were not significant compared to placebo.
    3 context sentences
    Summary · context
    Compared to baseline, teduglutide significantly improved the SBS-QoL™ total score and the score of 9 of 17 items at week 24.
    Summary · context
    QoL analyses from a double-blind, randomised Phase III study in 86 SBS-IF patients receiving teduglutide (0.05 mg/kg/day s.c.) or placebo over 24 weeks.
    Summary · context
    At baseline and every 4 weeks, QoL was assessed using the validated SBS-QoL™ scale.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In SBS-IF patients, improvements in SBS-QoL item scores with teduglutide were not significant compared with placebo at week 24.

    In plain wordsIn SBS-IF patients, quality-of-life item score improvements with teduglutide were not significant compared with placebo.

    Peptide
    Teduglutide
    Outcome
    No significant changeSBS-QoL item scores versus placebo
    Study

    n = 86

    Comparator
    Placebo
    Outcome group
    Quality of life · Whole body
    Studied dose
    0.05 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    These changes were not significant compared to placebo.
    3 context sentences
    Summary · context
    Compared to baseline, teduglutide significantly improved the SBS-QoL™ total score and the score of 9 of 17 items at week 24.
    Summary · context
    QoL analyses from a double-blind, randomised Phase III study in 86 SBS-IF patients receiving teduglutide (0.05 mg/kg/day s.c.) or placebo over 24 weeks.
    Summary · context
    At baseline and every 4 weeks, QoL was assessed using the validated SBS-QoL™ scale.
  3. 03HumanNon-randomized trialEfficacy outcome

    In SBS-IF patients, teduglutide significantly improved the SBS-QoL total score versus baseline at week 24.

    In plain wordsIn SBS-IF patients, teduglutide improved the total quality-of-life score versus baseline at week 24.

    Peptide
    Teduglutide
    Outcome
    Direction not reportedSBS-QoL total score versus baseline
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    0.05 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared to baseline, teduglutide significantly improved the SBS-QoL™ total score and the score of 9 of 17 items at week 24.
    2 context sentences
    Summary · context
    QoL analyses from a double-blind, randomised Phase III study in 86 SBS-IF patients receiving teduglutide (0.05 mg/kg/day s.c.) or placebo over 24 weeks.
    Summary · context
    At baseline and every 4 weeks, QoL was assessed using the validated SBS-QoL™ scale.
  4. 04HumanNon-randomized trialEfficacy outcome

    In SBS-IF patients, teduglutide significantly improved scores for 9 of 17 SBS-QoL items versus baseline at week 24.

    In plain wordsIn SBS-IF patients, teduglutide improved scores for 9 of 17 quality-of-life items versus baseline at week 24.

    Peptide
    Teduglutide
    Outcome
    Direction not reportedSBS-QoL item scores versus baseline
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    0.05 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    SBS-QoL items improved versus baseline at week 24
    9 items
    9 of 17 items, teduglutide 0.05 mg/kg/day

    Source sentences

    Summary
    Compared to baseline, teduglutide significantly improved the SBS-QoL™ total score and the score of 9 of 17 items at week 24.
    2 context sentences
    Summary · context
    QoL analyses from a double-blind, randomised Phase III study in 86 SBS-IF patients receiving teduglutide (0.05 mg/kg/day s.c.) or placebo over 24 weeks.
    Summary · context
    At baseline and every 4 weeks, QoL was assessed using the validated SBS-QoL™ scale.
  5. 05HumanObservational studySafety outcome

    In teduglutide-treated SBS-IF patients, those with remaining small intestine >100 cm experienced more gastrointestinal adverse events; the abstract does not name the comparison group.

    In plain wordsIn teduglutide-treated SBS-IF patients, those with over 100 cm of remaining small intestine had more gut adverse events than an unnamed comparison group.

    Peptide
    Teduglutide
    Outcome
    IncreaseGastrointestinal adverse events by remaining intestine length
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.05 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teduglutide-treated patients with remaining small intestine >100 cm experienced more gastrointestinal adverse events (GI-AE), unfavourably affecting QoL.
    2 context sentences
    Summary · context
    QoL analyses from a double-blind, randomised Phase III study in 86 SBS-IF patients receiving teduglutide (0.05 mg/kg/day s.c.) or placebo over 24 weeks.
    Summary · context
    At baseline and every 4 weeks, QoL was assessed using the validated SBS-QoL™ scale.
  6. 06HumanObservational studyEfficacy outcome

    In teduglutide-treated SBS-IF patients with remaining small intestine >100 cm, gastrointestinal adverse events unfavourably affected quality of life.

    In plain wordsIn teduglutide-treated SBS-IF patients with over 100 cm of remaining small intestine, gut adverse events were linked to worse quality of life.

    Peptide
    Teduglutide
    Outcome
    Direction not reportedQoL association with gastrointestinal adverse events
    Study

    n: not reported in source

    Outcome group
    Quality of life · Whole body
    Studied dose
    0.05 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Teduglutide-treated patients with remaining small intestine >100 cm experienced more gastrointestinal adverse events (GI-AE), unfavourably affecting QoL.
    2 context sentences
    Summary · context
    QoL analyses from a double-blind, randomised Phase III study in 86 SBS-IF patients receiving teduglutide (0.05 mg/kg/day s.c.) or placebo over 24 weeks.
    Summary · context
    At baseline and every 4 weeks, QoL was assessed using the validated SBS-QoL™ scale.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase not statedNCT04733066

Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis

Charite University, Berlin, Germanyn = 401 Sept 2020 to est. Sept 2022

Short Bowel Syndrome · Intestinal Failure

Trial pageClinicalTrials.govUpdated 1 Feb 2021
CompletedPhase 3Results postedNCT00798967

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Shiren = 8625 Nov 2008 to 25 Jan 2011

Short Bowel Syndrome

Trial pageClinicalTrials.govUpdated 3 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.